Amanda Watkins
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, CAR-T cell therapy research, Immune cells in cancer
Most-Cited Works
- → Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery(2016)412 cited
- → Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody(2015)402 cited
- → Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment(2020)209 cited
- → Loss of CD4+T Cell Proliferative Ability but Not Loss of Human Immunodeficiency Virus Type 1 Specificity Equates with Progression to Disease(2000)121 cited
- → Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery(2019)99 cited
- → The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment(2017)75 cited
- → A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist(2017)50 cited
- → Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer(2021)28 cited
- → Immune reconstitution in HAART-treated children with AIDS(1998)26 cited
- → Abstract 5017: MEDI1191, a novel IL-12 mRNA therapy for intratumoral injection to promote TH1 transformation of the patient tumor microenvironment(2019)10 cited